Skip to main content
OpenTrials
Completed

NCT Number: NCT06776926

Timing of Carbetocin Administration in Postpartum Hemorrhage

Postpartum haemorrhage (PPH) is one of the major contributors to maternal mortality and morbidity worldwide. Active management of the third stage of labour has been proven to be effective in the prevention of PPH. Syntometrine is more effective than oxytocin but is associated with more side effects. Carbetocin, a long-acting oxytocin agonist, appears to be a promising agent for the prevention of PPH. The use of carbetocin, being an important agent in the prevention of PPH, also increases its prevalence. It is planned to investigate the advantages and disadvantages of the timing of its use.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Postpartum Hemorrhage Carbetocin Female Urogenital Diseases and Pregnancy Complications Hemorrhage Obstetric Labor Complications Pathologic Processes Pathological Conditions, Signs and Symptoms Placenta Diseases Placenta, Retained Pregnancy Complications Puerperal Disorders Urogenital Diseases Uterine Hemorrhage

Age range

18 year–40 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Kartal Dr Lutfi Kirdar City Hospital

Istanbul, 34880, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Singleton pregnancy
  • Vaginal delivery at or beyond 38 weeks of gestation
  • Primipar

Exclusion criteria

  • Multiparity
  • Contraindications to carbetocin use (e.g., pre-existing hypertension, pre-eclampsia,asthma, cardiac, renal, or liver disease)
  • High-risk factors for primary postpartum hemorrhage, including grand multiparity,presence of uterine fibroids, or a need for prophylactic oxytocin infusion
  • Anemia or
  • body mass index (BMI) over 35
  • Baby weight over 4000 grams
  • Comorbidities or chronic diseases
  • History of curettage
  • Use of propess or oxytocin during labor

Treatment and study plan

Carbetocin

Behavioral

Use of carbetocin

Primary outcomes

  1. Carbetosin effect

    Time frame: 24 hours after delivery

    incidence of postpartum hemorrhage >500 ml (percent (%)), additional uterotonics using (yes/no), placenta retention (yes/no), adverse effects (hypotension (yes/no), tachycardia (yes/no), headache(yes/no) oliguria (yes/no)),

Sponsors and collaborators

Lead sponsor

Mehmet Mete Kırlangıç

Other Gov

Registry information

Official study title

When Should Carbetocin be Administered to Prevent Postpartum Hemorrhage After Normal Vaginal Delivery?

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jan 15, 2025
Registry last updated
Sep 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.